EichorEICHOR
Condition: Leukemia Chronic Lymphocytic Synced from ClinicalTrials.gov · August 06, 2026

Recruiting studies: Leukemia Chronic Lymphocytic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patie
Phase 2 · 13 location(s) · Center for International Blood and Marrow Transplant Researc · NCT06859424CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Unde
Phase 2 · 3 location(s) · City of Hope Medical Center · NCT060593913'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
EARLY_Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT06890494A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 4 · 49 location(s) · Eli Lilly and Company · NCT07218341CLL-IMPACT: A Clinical Nutrition Trial Investigating Immune and Metabolic Changes in Early-Stage CLL
NA · 1 location(s) · Technical University of Munich · NCT07487428Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Deg
Phase 1/Phase 2 · 29 location(s) · BeiGene · NCT05294731Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 · 1 location(s) · Seema Bhat · NCT06757647Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-inten
Phase 2 · 10 location(s) · University of Liege · NCT03852407Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Mod
Phase N/A · 8 location(s) · Bristol-Myers Squibb · NCT06357754AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
Phase N/A · 1 location(s) · AstraZeneca · NCT06548152ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Phase 3 · 5 location(s) · Newave Pharmaceutical Inc · NCT07342478A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic
Phase 3 · 5 location(s) · Grifols Biologicals, LLC · NCT07582432CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05442515Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphoc
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT03824483Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2
Phase 2 · 36 location(s) · AstraZeneca · NCT07024706Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · 631 location(s) · National Cancer Institute (NCI) · NCT04269902Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and
Phase 1/Phase 2 · 26 location(s) · Sellas Life Sciences Group · NCT04588922Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Phase 2 · 1 location(s) · Kerry Rogers · NCT06466122Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06958705Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
Phase 2 · 1 location(s) · Jennifer Woyach · NCT07685717Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematologi
Phase N/A · 5 location(s) · Medical University Innsbruck · NCT06821880Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Phase 1/Phase 2 · 23 location(s) · Incyte Biosciences International Sàrl · NCT03934372Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Phase 2 · 20 location(s) · University Hospital, Clermont-Ferrand · NCT04935684Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801Global Trial in APG2575 for Patients With CLL/SLL
Phase 3 · 135 location(s) · Ascentage Pharma Group Inc. · NCT06104566Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Le
Phase 2 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05336812Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06364423
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.